Complementary role of WB-MRI & FDG PET/CT on management of MM
Presented by Prof Claudio Cerchione (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Italy)
Prof Claudio Cerchione, a haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori in Meldola, Italy, presented pioneering research at the ASCO24 rapid oral abstract session. The study focused on the combined use of FDG PET/CT and whole-body MRI (WB-MRI) for staging newly diagnosed and relapsed/refractory multiple myeloma (MM).
In this prospective trial, 73 MM patients were enrolled, with 71 patients included in the final analysis. WB-MRI was performed alongside FDG PET/CT. Results showed a 73% concordance rate between WB-MRI and FDG PET/CT. In the 25% of discordant cases, 83% (15 out of 18) were negative on FDG PET/CT but positive on WB-MRI, while 17% (3 out of 18) were positive on FDG PET/CT for focal lesions but negative on WB-MRI. The accuracy of WB-MRI stood at 97% (69 out of 71), significantly higher than the 77% accuracy of FDG PET/CT (55 out of 71).
The study suggests that WB-MRI and FDG PET/CT can complement each other in managing MM patients at diagnosis and relapse stages. The next phase of this prospective research will combine imaging and molecular analyses to develop a risk-adapted prognostic index in MM.
References:
Cerchione C, ASCO24, #7512
With the educational support of:
